AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
AstraZeneca Showcases Groundbreaking Cancer Research at ASCO 2025 with Two Plenary Presentations
• AstraZeneca will present over 80 abstracts at ASCO 2025, including two plenary presentations featuring camizestrant for HR-positive breast cancer and IMFINZI for early gastric cancer, marking their seventh consecutive year with plenary data.
• The SERENA-6 trial is the first positive Phase III study for a next-generation oral SERD in first-line HR-positive breast cancer, pioneering the use of circulating tumor DNA to guide treatment decisions.
• DESTINY-Breast09 data shows ENHERTU plus pertuzumab is the first treatment in over a decade to demonstrate superiority over standard care in first-line HER2-positive metastatic breast cancer.
Pfizer Enters $6 Billion Licensing Deal with China's 3SBio for Novel Cancer Drug
• Pfizer has secured global rights (excluding China) to 3SBio's experimental cancer drug SSGJ-707 for $1.25 billion upfront, with potential additional payments of up to $4.8 billion based on developmental milestones.
• SSGJ-707 is currently being evaluated for multiple cancer types including non-small cell lung cancer, metastatic colorectal cancer, and gynecological tumors, with Phase III trials in China planned to begin this year.
• The deal includes a $100 million equity investment in 3SBio by Pfizer, with manufacturing planned at Pfizer's facilities in North Carolina and Kansas following FDA clearance of the Investigational New Drug application.
BATURA Trial: Airsupra Reduces Severe Asthma Exacerbation Risk by 47% Compared to Albuterol Alone
• AstraZeneca's Airsupra (albuterol/budesonide) demonstrated a 47% reduction in severe asthma exacerbation risk compared to albuterol alone in patients with mild asthma, according to the Phase IIIb BATURA trial.
• The anti-inflammatory rescue therapy reduced total systemic corticosteroid exposure by 63%, potentially decreasing risks associated with cumulative steroid use including diabetes, cardiovascular disease, and other adverse conditions.
• Results were so overwhelmingly positive that the Independent Data Monitoring Committee recommended early termination of the trial, suggesting a potential paradigm shift in asthma rescue treatment after 50 years of albuterol-only standard care.
Ruxoprubart Shows Promising Phase II Results as Novel Monotherapy for Paroxysmal Nocturnal Hemoglobinuria
• NovelMed's Ruxoprubart demonstrated significant efficacy in a Phase II trial for treatment-naïve PNH patients, meeting all primary endpoints including complete transfusion avoidance and increased hemoglobin levels.
• The drug's selective inhibition of the Alternative Pathway without affecting the Classical Pathway offers a potentially safer profile than existing treatments, which often carry Black Box warnings for infection risk.
• With FDA Orphan Drug Designation already secured and plans to file for Breakthrough Therapy Designation, Ruxoprubart is positioned as a potential best-in-class therapy for PNH and other complement-mediated disorders.
Merck and Daiichi Sankyo Launch Phase 3 Trial of Novel B7-H3 Targeted ADC for Advanced Esophageal Cancer
• The IDeate-Esophageal01 Phase 3 trial has begun evaluating ifinatamab deruxtecan, a potential first-in-class B7-H3 directed antibody-drug conjugate, against standard chemotherapy in advanced esophageal squamous cell carcinoma.
• Esophageal squamous cell carcinoma accounts for 90% of global esophageal cancers with dismal survival rates of 15-20%, highlighting the urgent need for new treatment approaches after first-line therapy failure.
• The trial follows promising early-phase results and will enroll approximately 510 patients across Asia, Europe, and North America, with overall survival as the primary endpoint.
AstraZeneca Acquires EsoBiotec for $1 Billion: Revolutionary In Vivo CAR-T Technology to Transform Cancer Treatment
• Belgian biotech EsoBiotec, founded by Congolese-born scientist Jean-Pierre Latere, has been acquired by AstraZeneca for $1 billion, including $425 million upfront and $575 million in milestone payments.
• EsoBiotec's groundbreaking Engineered NanoBody Lentiviral (ENaBL) platform enables in vivo CAR-T cell therapy, turning patients into their own cell therapy factories and potentially eliminating complex ex vivo manufacturing processes.
• The acquisition represents a remarkable success story for a capital-constrained startup that operated on just €22 million, compared to competitors who raised hundreds of millions for similar technology development.
Diabetes Drug Pioglitazone Shows Promising Anti-Tumor Effects in Prostate Cancer
• Researchers from the Medical University of Vienna have discovered that PPAR𝛾, a protein targeted by type 2 diabetes medications, can influence prostate cancer cell growth.
• The diabetes drug pioglitazone was found to inhibit tumor cell growth and metabolism in prostate cancer, suggesting potential repurposing opportunities for existing diabetes treatments.
• Initial clinical observations indicate that prostate cancer patients with diabetes who received PPAR𝛾 agonists showed no cancer relapse during the study period, warranting further investigation.
AstraZeneca's Breztri Shows Significant Improvement in Phase III Asthma Trials
• Breztri Aerosphere met all primary endpoints in KALOS and LOGOS Phase III trials, demonstrating statistically significant improvement in lung function for patients with uncontrolled asthma compared to dual-combination therapies.
• The triple-combination therapy (budesonide/glycopyrronium/formoterol fumarate) could potentially address a critical unmet need, as nearly half of asthma patients on dual therapy remain uncontrolled.
• AstraZeneca plans to share the full trial results with regulatory authorities, potentially expanding Breztri's approved indications beyond its current use in COPD treatment across 80+ countries.
Balancing Efficacy and Cost Sustainability in Modern CLL Treatment: Insights from Dr. Pierluigi Porcu
• Clinicians treating chronic lymphocytic leukemia (CLL) face growing challenges in balancing clinical efficacy with long-term cost sustainability, requiring a holistic approach to patient care.
• Dr. Pierluigi Porcu emphasizes that effective CLL management requires understanding disease risk, patient comorbidities, and practice environment constraints including payer considerations.
• Despite its importance, value-based care adoption remains insufficient in oncology, with challenges in defining and measuring value across patient outcomes, quality of life, and treatment costs.
UK Government Unveils Life Sciences Strategy to Strengthen Post-Brexit Industry
• The UK government has revealed a comprehensive life sciences strategy led by Professor Sir John Bell, aiming to strengthen the sector after Brexit through increased funding and policy reforms.
• Key proposals include £160 million in new funding, improved clinical trial capabilities, implementation of the Accelerated Access Review, and benchmarking the UK to be in the top quartile for innovative medicine adoption by 2023.
• Industry leaders from pharmaceutical companies, biotech firms, and healthcare organizations collaborated on the strategy, which addresses challenges in NHS funding constraints while seeking to create a globally competitive life sciences ecosystem.
AstraZeneca Acquires EsoBiotec for Up to $1 Billion to Transform Cancer Cell Therapy
• AstraZeneca has agreed to acquire Belgium-based EsoBiotec for up to $1 billion, with an initial payment of $425 million and additional milestone-based payments of up to $575 million.
• EsoBiotec's Engineered NanoBody Lentiviral (ENaBL) platform enables in vivo modification of immune cells, potentially reducing cell therapy delivery time from weeks to minutes through a simple injection.
• The acquisition, expected to close in Q2 2025, aims to revolutionize cancer treatment by making cell therapies more accessible and efficient for patients while expanding AstraZeneca's oncology portfolio.
Roche Expands Molecular Glue Portfolio with $2 Billion Monte Rosa Partnership
• Roche has signed a $2 billion partnership with Monte Rosa Therapeutics, including a $50 million upfront payment, to develop molecular glue therapies targeting previously "undruggable" proteins in cancer and neurological diseases.
• This marks Roche's second major molecular glue deal in a month, following a similar $2 billion alliance with Orionis Biosciences, demonstrating the company's strategic push to establish leadership in this emerging therapeutic category.
• Monte Rosa will lead discovery and preclinical activities using its QuEEN platform, with Roche taking over late-stage development of candidates that can potentially address the 80% of human proteins currently inaccessible to traditional drug development approaches.
Ionis and Ono Forge $940 Million Deal for Sapablursen in Polycythemia Vera Treatment
• Ionis Pharmaceuticals has licensed sapablursen, an RNA-targeted medicine for polycythemia vera, to Ono Pharmaceutical in a deal worth up to $940 million including $280 million upfront.
• Sapablursen, currently in Phase 2 trials, has received FDA Fast Track and Orphan Drug designations and works by increasing hepcidin production to regulate iron homeostasis in PV patients.
• Ono will gain exclusive global rights for development and commercialization, while Ionis will complete the ongoing IMPRSSION study before transferring responsibilities.
EU Approves WAINZUA (Eplontersen) for Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy
• The European Commission has approved WAINZUA (eplontersen), developed by Ionis Pharmaceuticals and AstraZeneca, for treating hereditary transthyretin-mediated amyloidosis with polyneuropathy (ATTRv-PN) in adult patients with stage 1 or 2 disease.
• WAINZUA is the only EU-approved treatment for ATTRv-PN that can be self-administered monthly via an auto-injector, offering consistent TTR protein suppression and improvements in neuropathy impairment and quality of life.
• The approval follows positive results from the NEURO-TTRansform Phase 3 trial, which demonstrated sustained benefits through 66 weeks on serum TTR concentration, neuropathy impairment, and quality of life compared to placebo.
FDA Grants Priority Review to Dupixent for Bullous Pemphigoid Treatment
• The FDA has accepted Dupixent's supplemental biologics license application for priority review in treating bullous pemphigoid, with a decision expected by June 20, 2025.
• Pivotal trial results showed five times more patients achieving sustained disease remission with Dupixent compared to placebo, demonstrating significant improvements in disease severity and itch reduction.
• Approximately 27,000 adults in the US suffer from bullous pemphigoid uncontrolled by systemic corticosteroids, representing a significant unmet medical need in this elderly population.
AbbVie's Telisotuzumab Vedotin Shows Promise in c-Met Overexpressing NSCLC
• AbbVie's telisotuzumab vedotin (Teliso-V) demonstrated a 35% overall response rate in patients with high c-Met expression in the LUMINOSITY trial.
• The FDA granted breakthrough therapy designation to Teliso-V, highlighting its potential to significantly improve outcomes in NSCLC patients.
• A phase 3 trial (TeliMET-NSCLC-01) is underway, comparing Teliso-V to docetaxel in c-Met-positive, non-squamous NSCLC patients.
• Teliso-V targets c-Met, a protein involved in cancer progression and resistance to therapies like EGFR inhibitors, offering a novel approach.
J&J's Rybrevant and Lazcluze Combo Shows Survival Benefit Over Tagrisso in Lung Cancer
• Johnson & Johnson's Rybrevant and Lazcluze combination therapy significantly improved overall survival compared to AstraZeneca's Tagrisso in first-line NSCLC.
• The MARIPOSA trial demonstrated a clinically meaningful and statistically significant survival benefit, potentially exceeding one year compared to Tagrisso.
• This combination therapy targets both EGFR and MET pathways, offering a new approach to combat resistance in EGFR-mutated non-small cell lung cancer.
• While effective, the Rybrevant/Lazcluze regimen presents challenges including infusion administration and a higher rate of side effects compared to Tagrisso.
© Copyright 2025. All Rights Reserved by MedPath